Tumor Vascular Proteins As Biomarkers in Ovarian Cancer
- 1 March 2007
- journal article
- gynecologic cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (7), 852-861
- https://doi.org/10.1200/jco.2006.08.8583
Abstract
Purpose This study aimed to identify novel ovarian cancer biomarkers and potential therapeutic targets through molecular analysis of tumor vascular cells. Methods Immunohistochemistry-guided laser-capture microdissection and genome-wide transcriptional profiling were used to identify genes that were differentially expressed between vascular cells from human epithelial ovarian cancer and healthy ovaries. Tumor vascular markers (TVMs) were validated through quantitative real-time polymerase chain reaction (qRT-PCR) of immunopurified tumor endothelial cells, in situ hybridization, immunohistochemistry, and Western blot analysis. TVM expression in tumors and noncancerous tissues was assessed by qRT-PCR and was profiled using gene expression data. Results We identified a tumor vascular cell profile of ovarian cancer that was distinct from the vascular profile of normal ovary and other tumors. We validated 12 novel ovarian TVMs. These were expressed by immunopurified tumor endothelial cells and localized to tumor vasculature. Select TVMs were found to be specifically expressed in ovarian cancer and were absent in all normal tissues tested, including female reproductive tissues with physiologic angiogenesis. Many ovarian TVMs were expressed by a variety of other solid tumors. Finally, overexpression of any one of three ovarian TVMs by vascular cells was associated with decreased disease-free interval (all P < .005). Conclusion We have identified for the first time the molecular profile of ovarian tumor vasculature. We demonstrate that TVMs may serve as potential biomarkers and molecular targets for ovarian cancer and a variety of other solid tumors.This publication has 23 references indexed in Scilit:
- Tumor Angiogenesis and Molecular Target Therapy in Ovarian CarcinomasHuman Cell, 2008
- Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasmsGynecologic Oncology, 2006
- Systemic Therapy for Ovarian Cancer: Current Status and New TreatmentsSeminars in Oncology, 2006
- Oncogenic pathway signatures in human cancers as a guide to targeted therapiesNature, 2005
- Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecologic Oncology, 2005
- The Application of Rule-Based Methods to Class Prediction Problems in GenomicsJournal of Computational Biology, 2003
- Exploration, normalization, and summaries of high density oligonucleotide array probe level dataBiostatistics, 2003
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Specialization of tumour vasculatureNature Reviews Cancer, 2002
- IF-LCM: Laser capture microdissection of immunofluorescently defined cells for mRNA analysisKidney International, 2000